

NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
SEPTEMBER 16, 2014

CALL TO ORDER / ANNOUNCEMENTS

The NCI @ F Institutional Biosafety Committee was convened at 12:04 pm in Building 549 Executive Board Room with the following members in attendance:

Voting (Quorum = 8)

- | | |
|---|--|
| <input checked="" type="checkbox"/> Katalin Baranji | <input checked="" type="checkbox"/> Stephen Hughes |
| <input type="checkbox"/> Michael Baseler (<i>regrets</i>) | <input checked="" type="checkbox"/> Sarah Hooper |
| <input checked="" type="checkbox"/> Theresa Bell | <input checked="" type="checkbox"/> Serguei Kozlov |
| <input checked="" type="checkbox"/> Rev. David Betzner | <input checked="" type="checkbox"/> Dan McVicar |
| <input checked="" type="checkbox"/> Stephen Creekmore | <input checked="" type="checkbox"/> Raja Sriperumbudur |
| <input checked="" type="checkbox"/> Bruce Crise | <input type="checkbox"/> Lucien Winegar (<i>regrets</i>) |
| <input type="checkbox"/> Eric Freed (<i>regrets</i>) | <input checked="" type="checkbox"/> Enrique Zudaire |
| <input checked="" type="checkbox"/> Melinda Hollingshead | <input type="checkbox"/> Sharon Altmann (<i>regrets</i>) |

Non-Voting

- Walter Hubert
- Karen Barber
- Matthew Nawn

APPROVAL OF MINUTES FROM AUGUST 19 MEETING

The minutes from the August 19, 2014 meeting were approved with one minor change. A motion and second were made. (For: 12; Against: 0; Abstain: 0)

ACCIDENT REVIEWS : None

REVIEW OF PROTOCOLS

NEW REGISTRATIONS

Thomas Turbyville – 14-30 – Ras Project 3 – This project entails developing imaging based assays to study the localization of fluorescently tagged proteins in mammalian cells. Cells are transiently and stably transfected with plasmid DNA's that contain recombinant genes that encode fluorescent proteins and the protein of interest. These cells are then imaged on optical microscopes. The images provide precise information about the location of the proteins of interest in cells. HeLa and MDCK cell lines only. Viral transfection performed by R. Bagni (IBC 13-06) and D. Esposito will perform the plasmid DNA transfection (IBC 13-35). Conditional approval pending updates to the registration. T. Bell motioned to approve; K. Baranji seconded. (For: 12; Against: 0; Abstain: 0)

Deborah Morrison – 14-31 – Functional characterization of the Raf protein kinase family and their modulators. The purpose of the project will be to study the biological role of the Raf family of protein

NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
SEPTEMBER 16, 2014

kinases as they function in the growth and survival pathways that regulate normal cells, as well as their dysfunction in disease states. We will also study the proteins that modulate the activity of the Raf family during normal and aberrant cell growth. This will generate recombinant DNA constructs as well as replication-deficient recombinant viruses for both the expression and silencing of wild type and mutant proteins in established cell culture systems. No viral material will be administered to animals. S. Kozlov motioned to approve pending updates to the registration. K. Zudaire seconded. (For: 12; Against: 0; Abstain: 0)

William Gillette – 14-28 – Recombinant protein expression and purification – The objective of this study is to supply proteins to NCL, FNL Ras Project, other federal labs and entities that fall under the scope of the contract. Proteins are produced in micro-organisms (E.coli, yeast), insect cells and human cells. B. Crise motioned to approve pending updates to the registration; T. Bell seconded. (For: 12; Against: 0; Abstain: 0)

Howard Young – 14-33 – Role of IFN-gamma in oncogenesis, metastasis and drug resistance in melanoma – IFN-gamma is known for the cytostatic/cytotoxic and antitumor activities during cell-mediated adaptive immune response. We will design experiments where specific lymphocyte subsets are depleted from the host in order to define the role for these subsets in the observed phenotypes. Specifically, we will be challenging the mice for tumor growth and metastasis only with murine melanoma cells derived from the C57BL6/L background. S. Hughes motioned to approve pending updates to the registration; M. Hollingshead seconded. (For: 12; Against: 0; Abstain: 0)

RENEWALS

Mary Carrington – 14-34 (12-01) – Influence of genetic polymorphism on human disease – The objective of this project is to determine the link between variations in human genes and disease outcomes. We study genetic loci involved in immune responses including human leukocyte antigen (HLA), killer cell immunoglobulin like receptor (KIR) genes and others. Associations between the genetic variants and disease pathogenesis are interrogated further by performing in vitro experiments to understand the mechanism of the genetic influence on disease. Sriperumbudur motioned to approve pending updates to the registration; T. Bell seconded. (For: 12; Against: 0; Abstain: 0)

Simone Difilippantonio – Determination of toxicity, pharmacokinetics and efficacy of investigational compounds – This IBC protocol is an umbrella type proposal and covers the use of in vivo models engrafted with human cells (xenograft) followed by administration of experimental compounds to monitor efficacy based on tumor regression or extended survival. LASP staff will provide the technical support for all phases on the animal work and handling the compounds. B. Crise motioned to approve pending updates to the registration; R. Sriperumbudur seconded. (For: 12; Against: 0; Abstain: 0)

NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
SEPTEMBER 16, 2014

Peter Gorelick – 14-26 (08-27). Serological diagnostic testing of non-human primates for the presence of potentially adventitious viruses - Diagnostic serological testing for routine health monitoring of NHPs. (Bell) Deferred to full committee in August. Awaiting additional documentation.

OUTSTANDING ITEMS

John Gilly – 14-23 – Storage of BARDA Vaccine Materials. (McVicar/Creekmore). The purpose of this project is solely to store materials that were generated by MedImmune for the development of pandemic influenza live attenuated vaccines for BARDA/HHS. Moved to approve with the clarification that although there are no safety issues, it seems impossible to attest to the contents of the material. The committee voted to raise the issue to NCI management to obtain their concurrence on this request prior to issuing IBC approval. On September 3, 2014, the IBC received formal approval from NCI to store the material. D. McVicar motioned to approve; S. Hughes seconded. (For: 12; Against: 0; Abstain: 0)

Sivakumarvenkat Vepachedu – 14-27 – PTEN-long - Recombinant human PTEN protein, expressed and purified from bacteria, is commercially available as a reagent for research and development studies. The objectives of this PTEN-long project are; i) conduct analytical assays on PTEN-Long produced in Dr. Parson's lab, ii) R&D production to perform toxicology, PK and PD studies, and iii) medium scale and GMP production. This registration is being kept open until the Milestone 1 is completed. Once Milestone 1 is completed, the PI will re-issue this registration with the appropriate changes for Milestone 2. D. McVicar motioned to approve pending updates to the registration; T. Bell seconded. (For: 12; Against: 0; Abstain: 0). ***It was determined that Milestone 1 does not require IBC review or registration. Therefore, the IBC submittal for production activities will be held until a later date.***

Vinay Vyas – 14-29 – Process Development and Clinical Manufacture of Mammalian Interleukin 7 - Interleukin-7 (IL-7) is a multifunctional cytokine with critical and non-redundant roles in T lymphocyte development, hematopoiesis, and post-developmental immune functions. Recombinant human Interleukin 7 (rhIL-7) is being developed as anti-tumor as well as anti-infectious reagent for clinical trials. Recombinant human Interleukin 7 (rhIL-7) has previously been produced at the BDP using an E. coli expression system. The BDP is developing a new mammalian cell based transient expression system for rhIL-7. Transient expression systems are widely used in industry at the early stage of pre-clinical product development. Advantages of transient expression system use in early product development include low cost, rapid development of a production cell line, and rapid generation of sufficient material for characterization. Dr. McVicar motioned to approve pending updates to the registration and B. Crise seconded. (For: 12; Against: 0; Abstain: 0)

Stephen Lockett – 14-22 (08-46) – Ras project 3 and CCR support. Discovery methods to directly target oncogenic Ras protein, and live and fixed cell fluorescence labeling in support of CCR research. (Zudaire/Hughes/Altmann) Deferred to full committee in August. Awaiting additional documentation. ***ON HOLD. WAITING ON CHANGES IN THE DEPARTMENT BEFORE SUBMITTING. As of October 14, 2014, no updates have been made.***

NATIONAL CANCER INSTITUTE AT FREDERICK (NCI@F)
INSTITUTIONAL BIOSAFETY COMMITTEE
MINUTES
SEPTEMBER 16, 2014

James McMahon – 14-24 (P191187JMA) – MTL Antiviral Screening Group. The testing of compounds for anti-HIV activity in a live virus, cell-based assay. (Sriperumburdur/Kozlov) Deferred to full committee in August. Awaiting additional documentation. The PI met with Dr. Freed for assistance. The registration is now ready for full committee in October.

Dimiter Dimitrov 13-38 (04-04, 08-20): *Developing anti-viral vaccines and human antibodies against infectious diseases and cancer antigens by using recombinant membrane proteins of HIV, Nipah, Hendra, Denque viruses and cancer antigens.* Committee requested additional clarifications and a Vaccinia-specific SOP as well as a lab visit. Post-meeting, Theresa Bell learned that the lab was relocating and suggested that the space that will be used for the Vaccinia work should not be evaluated until the move has been completed. No Vaccinia work is being performed at this time. **Continue deferral until lab move and observation is completed.** For: 8; Against: 0; Abstain: 0

AMENDMENTS

Randy Stevens – 11-40-A1 – The AIDS Monitoring Lab (AML) is currently approved to work with blood and body fluids from patients vaccinated with an Adenoviral vector under this registration. Due to a recent, urgent request from NIAID, this amendment is to include work with blood from healthy patients receiving a novel vaccine to Ebola using a recombinant vesicular stomatitis virus (VSV). This was reviewed by Dan McVicar, but needs to go to full committee. Dr. McVicar motioned to approve and S. Kozlov seconded. (For: 12; Against: 0; Abstain: 0)

Twenty four amendments were processed and approved between August and September IBC meetings.

OTHER BUSINESS

- Toxoplasma Gondii work with germ free mice in building 550. SOP needs to be generated by LASP as well as modification to the ASP and IBC. It was suggested that a small committee be formed to review the processes.

ADJOURNMENT

The meeting adjourned at 2:40 pm.

Next meetings:

October 21, 2014

November 18, 2014